-

Seek Labs Appoints Kim Wirthlin as Chief Strategy Officer

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a healthcare innovations company developing diagnostic and therapeutic solutions that have the potential to revolutionize the detection and treatment of diseases, is pleased to announce the appointment of Kim Wirthlin as Chief Strategy Officer, effective March 17, 2025. Wirthlin brings more than 25 years of experience in university leadership, government relations, academic healthcare, and early-stage company development. As Chief Strategy Officer, Wirthlin will lead Seek Labs’ strategic initiatives, strengthening partnerships and expanding the company’s influence as global healthcare innovators.

As Chief Strategy Officer, Wirthlin will lead Seek Labs’ strategic initiatives, strengthening partnerships and expanding the company’s influence as global healthcare innovators.

Share

Prior to joining Seek Labs, Wirthlin served as President and COO of the Huntsman Cancer Foundation, where she led philanthropic strategies that supported groundbreaking cancer research and advanced clinical care. Prior to that, she spent 18 years as a member of the executive management team at University of Utah Health, where she solidified her reputation as a strong strategist in higher education and healthcare.

“Kim’s deep expertise in healthcare strategy, government affairs, and early-stage company growth will be instrumental in driving Seek Labs through our next phase of innovation and expansion,” said Jared Bauer, CEO of Seek Labs. “I am confident her leadership and insight will enhance our strategic initiatives as we continue to develop cutting-edge diagnostic and therapeutic solutions.”

Beyond her extensive work in academia and healthcare, Wirthlin has actively contributed to the start-up ecosystem as a mentor, advisor, and board member for emerging healthcare companies. She also served as CEO for two early-stage companies, bringing hands-on experience in scaling innovative ventures. In addition to her professional achievements, Wirthlin is deeply engaged in community service. She previously served as board chair for the Fourth Street Clinic, a healthcare provider for individuals experiencing homelessness. She continues to serve on the Fourth Street Clinic’s capital campaign committee and is an executive committee member of the International Women’s Forum.

“I’m honored to join Seek Labs at such a pivotal time in its growth,” said Wirthlin. “The company’s mission to transform healthcare through innovation aligns with my passion for bringing accessible and transformative healthcare solutions to people around the world. I look forward to contributing to Seek Labs’ vision and impact.”

About Seek Labs

Seek Labs is a privately held biotechnology company founded in 2016 and based in Salt Lake City, Utah. The company is dedicated to advancing research and solutions aimed at improving global health. Today, Seek Labs is developing point-of-care molecular diagnostic technologies and programmable target ablation therapeutics designed to transform disease detection and treatment. Seek Labs is a proud member of the BioHive, a collective representing the life sciences and healthcare innovation ecosystem in Utah.

Contacts

Bridget Baldwin
Director of Communications, Seek Labs
communications@seeklabs.com

More News From Seek Labs

Seek Labs to Sponsor and Exhibit at the 2024 Next Generation Dx Summit in Washington, D.C.

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and a novel CRISPR-based pharmaceutical technology platform, is excited to announce its sponsorship and participation in the upcoming 2024 Next Generation Dx Summit, hosted by Cambridge Healthtech Institute from August 19-21, 2024, in Washington, D.C. This event brings together global leaders to discuss cutting-edge advancements in diagnostic technol...

Renowned African Swine Fever Researcher, Douglas Gladue, PhD, joins Seek Labs as Vice President of Veterinary Pharmaceutical Development

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs names Dr. Douglas Gladue as VP of Veterinary Pharmaceutical Development....

Seek Labs Announces Successful Completion of African Swine Fever Virus In Vivo Trial Utilizing CRISPR-based Treatments

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based gene therapies, announced today the successful completion of a therapeutic trial using innovative CRISPR-based technologies to target the African Swine Fever Virus (ASFV) in pigs. The trial, which aimed to replicate and expand an earlier trial, demonstrated pigs infected with ASFV and treated with Seek Labs’ CRISPR-based system...
Back to Newsroom